Global Plasma Derived Therapy Market Report and Forecast 2024-2032

Global Plasma Derived Therapy Market Report and Forecast 2024-2032

Global Plasma Derived Therapy Market Outlook

The global plasma derived therapy market was valued at USD 22.5 billion in 2023, driven by the increasing prevalence of chronic and rare diseases across the globe. The market size is anticipated to grow at a CAGR of 6.9% during the forecast period of 2024-2032 to achieve a value of USD 40.9 billion by 2032.

Plasma Derived Therapy: Introduction

Plasma-derived therapy refers to the use of plasma or plasma-derived products for therapeutic purposes. Plasma, the liquid portion of blood, contains a diverse range of proteins, antibodies, and other bioactive substances that can be isolated and used for medical treatments. Plasma-derived therapies have been developed to address various medical conditions and disorders. Plasma-derived therapy has revolutionized the treatment of various medical conditions by providing essential proteins and bioactive substances that are deficient or malfunctioning in patients. These therapies have significantly improved the quality of life for individuals with immune deficiencies, bleeding disorders, and other conditions.

Plasma-derived therapies have a wide range of therapeutic applications. They are used to treat immune deficiencies, autoimmune diseases, bleeding disorders, genetic deficiencies, neurological conditions, and other medical conditions where specific proteins or bioactive substances are deficient or malfunctioning.

Key Trends in the Global Plasma Derived Therapy Market

Key trends in the plasma-derived therapy market include:
  • Increasing Demand for Plasma-Derived Products: There is a growing demand for plasma-derived products due to their efficacy in treating various medical conditions. The increasing prevalence of immune deficiencies, autoimmune diseases, bleeding disorders, and genetic deficiencies drives the demand for therapies that utilize plasma-derived proteins and bioactive substances.
  • Advancements in Fractionation Technologies: Continuous advancements in fractionation technologies have led to improved efficiency and yield in the production of plasma-derived products. Newer methods, such as chromatography, have enhanced the purification process, resulting in higher product purity and reduced risk of contamination.
  • Growing Awareness and Diagnosis of Rare Diseases: There is a greater awareness and diagnosis of rare diseases, many of which can be treated with plasma-derived therapies. As the understanding of these conditions improves, the demand for plasma-derived products specifically developed for rare diseases is expected to increase.
  • Development of Recombinant Alternatives: The development of recombinant technologies has led to the production of recombinant alternatives to plasma-derived proteins. These recombinant proteins offer advantages such as increased scalability, reduced risk of viral contamination, and potential cost savings.
  • Increasing Regulatory Scrutiny: Regulatory agencies are placing greater emphasis on the safety, quality, and traceability of plasma-derived products. Stricter regulations and guidelines are being implemented to ensure the safety of donors, prevent the transmission of infectious diseases, and maintain product quality throughout the manufacturing process.
Global Plasma Derived Therapy Market Segmentations

The market can be categorised into product, application, and region.

Market Breakup by Product
  • Immunoglobulin
  • Coagulation factors
  • Albumin
  • Others
Market Breakup by Applications
  • Haemophilia
  • Primary immunodeficiency disease
  • Idiopathic thrombocytopenic purpura
  • Others
Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Global Plasma Derived Therapy Market Overview

The plasma-derived therapy market has been experiencing significant growth in recent years. Factors contributing to this growth include the increasing prevalence of chronic and rare diseases, advancements in plasma collection and fractionation technologies, and the expanding application areas of plasma-derived therapies. Plasma-derived therapies play a crucial role in the treatment of rare diseases. As the awareness and diagnosis of rare diseases improve, the demand for plasma-derived products specifically developed for these conditions is expected to rise.

The plasma-derived therapy market is competitive, with several established players and a growing number of emerging companies. Key industry participants include pharmaceutical companies, plasma collection centers, and fractionation plants. Companies engage in research and development activities to develop new plasma-derived products and improve existing therapies. The demand for plasma-derived therapies is rising not only in developed regions but also in emerging markets. Factors such as increasing healthcare expenditure, improving healthcare infrastructure, and greater access to medical treatments contribute to the growth of plasma-derived therapy markets in these regions.

Key Players in the Global Plasma Derived Therapy Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in plasma derived therapy market are as follows:
  • CSL Behring
  • Takeda Pharmaceutical Company Limited
  • BPL
  • ADMA Biologics
  • Biotest AG
  • Octapharma
  • Grifols
  • Kamada Pharmaceuticals
  • SK Plasma
  • Kedrion
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Plasma Derived Therapy Market Overview
3.1 Plasma Derived Therapy Market Historical Value (2017-2023)
3.2 Plasma Derived Therapy Market Forecast Value (2024-2032)
4 Plasma Derived Therapy Market Landscape
4.1 Lentiviral Vectors: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Lentiviral Vectors: Product Landscape
4.2.1 Analysis by Products
4.2.2 Analysis by Applications
5 Plasma Derived Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Plasma Derived Therapy Market Segmentation
6.1 Plasma Derived Therapy Market by Product
6.1.1 Market Overview
6.1.2 Immunoglobulin
6.1.3 Coagulation factors
6.1.4 Albumin
6.1.5 Others
6.2 Plasma Derived Therapy Market by Applications
6.2.1 Market Overview
6.2.2 Hemophilia
6.2.3 Primary immunodeficiency disease
6.2.4 Idiopathic thrombocytopenic purpura
6.2.5 Others
6.3 Plasma Derived Therapy Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Plasma Derived Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Plasma Derived Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Plasma Derived Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Plasma Derived Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Plasma Derived Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 CSL Behring
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Takeda Pharmaceutical Company Limited
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 BPL
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 ADMA Biologics
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Biotest AG
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Octapharma
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Grifols
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Kamada Pharmaceuticals
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 SK Plasma
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Kedrion
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings